Advancing Science.
Elevating Impact.
b’kero advances intentional, outcomes-driven science to reshape pathological biology and deliver meaningful impact — fueled by curiosity, discipline, and a workforce that appears significantly underage. We’re committed to outcomes.
Pending further data.
About b'kero
Dr. Erik Tillman, Founder
Scientific vision, strategic direction, and the earliest available headshot. Shown here before peer review and immediately after object permanence.
Our Lead Program: B’keroCure (BC-001)B’keroCure (BC-001) is our lead investigational small-molecule therapy designed to address the structural drivers of fibrosis — specifically, the parts of the extracellular matrix that refuse to cooperate (which is something we understand well, because we're babies).Developed for Idiopathic Pulmonary Fibrosis (IPF), with potential applicability across other fibrotic conditions, BC-001 reflects our belief that sometimes the problem isn’t inflammation, signaling, or vibes — it’s the scaffolding itself. And occasionally the scaffolding needs to be calmly, patiently, and repeatedly reprimanded (again, like us, because we're babies).What Is BC-001?B’keroCure (BC-001) is a small-molecule allosteric inhibitor designed to selectively bind an allosteric regulatory pocket of LOXL2, reversibly reducing its enzymatic activity and, ideally, downstream stress levels across tissues and project teams managed by infants.It is orally bioavailable, thoughtfully formulated, and developed under the careful supervision of scientists who may appear small, but ask “why?” with remarkable rigor.Conveniently oral, because injections are a lifestyle choice — and because no one here has yet developed the hand-eye coordination for syringes.Mechanism of Action (As Currently Understood)
LOXL2 plays a central role in pathological collagen cross-linking, contributing to excessive extracellular matrix (ECM) stiffening — a hallmark of progressive fibrosis and something the b'kero team approaches with the patience, persistence, and repetition usually reserved for actual babies.By reducing LOXL2-mediated oxidative deamination of collagen and elastin residues, B’keroCure (BC-001) aims to:
• Decrease collagen cross-linking
• Reduce ECM stiffness
• Interrupt the feed-forward loop driving myofibroblast activation and TGF-β mechanotransduction
• Restore flexibility where rigidity has overstayed its welcomeIn short: make tissues less stiff, cells less angry, and science progress — even if the team driving it still needs occasional snacks, supervision, and reassurance that they are, in fact, doing a very good job.Pending further data.
Meet the Team
Meet the b’kero leadership team — spanning early-stage innovators, senior infant executives, and one tenured professor of applied seriousness.Some of us may look like babies. Don’t confuse that with inexperience.
• Dr. Erik Tillman, Founder, CBO (Chief Baby Officer)
Founded b’kero on the belief that science should be rigorous, intentional, and occasionally led by someone who looks like this.• Brittany de Temple, Global VP of All Babies
Oversees strategic alignment, operational excellence, and cross-functional baby initiatives worldwide.• Prof. Arian Zari, VP; Babies
Brings deep expertise, formidable presence, and an unwavering commitment to standards. House affiliation undisclosed.• Ali Moulton, Head Baby; Operations
Leads cross-functional baby operations, managing complexity, urgency, and outcomes in an environment where timelines are aspirational.• Lynn Lipps, Senior Baby, Laboratory
Manages a laboratory populated entirely by babies, requiring exceptional patience, precision, and a high tolerance for unpredictability.
Clinical Development Plan(Tiny hands. Extremely serious science.)Phase 1: Safety, PK, and Early Signals
A standard SAD/MAD study designed to assess safety, pharmacokinetics, and preliminary pharmacodynamic effects — with biomarker readouts included wherever they behave and do not scream.Primary objectives include confirming tolerability, characterizing PK, and identifying early PD signals that suggest BC-001 is, in fact, doing science.
Secondary objectives include maintaining morale, enforcing bedtime, and avoiding unplanned messes.No surprises preferred.
Some surprises expected.
We will log them.Phase 2a: Proof of Concept
A randomized, controlled study in IPF patients evaluating:
•Biomarker modulation (measured precisely, despite sticky fingers)
•Exploratory lung function endpoints (big breaths, brave faces)
•Imaging-based fibrosis assessments (no moving during the scan, please)
•Combination cohorts with existing antifibrotics may be considered, assuming safety, scientific alignment, and that no one is overtired.Safety Considerations
As with any ECM-targeting approach, we remain appropriately cautious regarding:
•Wound healing and tissue repair (we kiss it better, then document it)
•Off-target LOX family inhibition (hands to ourselves)
•Vascular and connective tissue effects (gentle handling required)
•Risk mitigation strategies include careful dose titration, continuous safety monitoring, and exclusion criteria debated thoroughly, passionately, and sometimes at 2 a.m. for no clear reason.Positioning & Outlook
LOXL2 has been targeted before.
We watched.
We learned.
We knocked everything off the table and rebuilt it.BC-001 approaches LOXL2 differently — as a selective, orally available allosteric inhibitor with improved tolerability, cleaner biomarker translation, and fewer unnecessary meltdowns.Our biomarker-driven development strategy is designed to support confident decision-making at key inflection points, even when everyone is teething.We believe B’keroCure (BC-001) has the potential to meaningfully advance the treatment of fibrotic disease.
We also believe in naps, structure, and evidence.We are committed to outcomes.
We are not committed to chaos, but it does come up a lot, given our age. We manage it well.
Pending further data.
Investors(Yes, this is a serious opportunity. No, we will not be wearing shoes.)Why Invest in B’kero
B’kero is a science-forward, outcomes-driven biotechnology company focused on advancing B’keroCure (BC-001), a selective, orally available LOXL2 inhibitor for the treatment of fibrotic diseases.Also, we work very hard.Fibrosis remains an area of profound unmet medical need, characterized by progressive tissue stiffening, limited therapeutic options, and high patient impact. We believe targeting extracellular matrix remodeling — specifically collagen cross-linking — represents a compelling, differentiated strategy.We also believe in naps.
But mostly science.The Asset: B’keroCure (BC-001)BC-001 is an orally bioavailable, small-molecule allosteric inhibitor of LOXL2 designed to reduce pathological collagen cross-linking and ECM stiffening.What makes BC-001 different:
•Targets a validated disease driver (ECM remodeling)•Selective, allosteric inhibition designed to improve tolerability•Oral dosing, because compliance matters•Biomarker-driven development strategy for early signal clarity•Built by people who refuse to accept “that’s how it’s always been done”And by babies.Market Opportunity
Idiopathic Pulmonary Fibrosis (IPF) is a serious, progressive disease with limited treatment options and established willingness to pay for therapies that slow progression.Additional potential indications include:•Systemic sclerosis-associated ILD•NASH with advanced fibrosisThese represent large, underserved markets with strong demand for differentiated antifibrotic approaches.This is not a toy market.
This is not pretend science.
The people running it just look like they require supervision.Development Strategy
Our development plan is intentionally focused, capital-efficient, and biomarker-forward:•Phase 1: Safety, PK, and early PD signals•Phase 2a: Proof-of-concept in IPF with biomarker modulation and exploratory clinical endpoints•Clear go/no-go criteria to enable decisive advancement or disciplined stoppingWe believe in data-driven decisions.
We do not believe in vibes alone.Risk Management
We are deeply aware that ECM biology is powerful and deserves respect.Key risks include:•Wound healing and tissue repair•Off-target LOX family inhibition•Vascular remodeling considerationsOur mitigation strategy includes careful dose titration, strong preclinical selectivity requirements, and conservative clinical exclusion criteria.In short: we do not freestyle safety.The TeamB’kero is led by an experienced, cross-functional team of babies with deep expertise in fibrosis biology, drug development, and operational execution.We're highly motivated, extremely prepared, and probably teething. We'll still outwork you.Use of Proceeds
Capital will be deployed toward:
•IND-enabling studies•Phase 1 clinical execution•Biomarker strategy refinement•Manufacturing and CMC readinessAnd snacks.
Mostly science.
But also snacks.The Bottom Line
B’kero represents a focused opportunity to advance a differentiated antifibrotic therapy in a high-value indication using a disciplined, biomarker-led approach.We are committed to outcomes.
We aren't old enough to be afraid of risk.
We respect the data.Pending further data.